clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Insulin Resistance D007333 99 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Arteriosclerosis D001161 86 associated lipids
Stomach Ulcer D013276 75 associated lipids
Hyperlipidemias D006949 73 associated lipids
Colitis D003092 69 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Pain D010146 64 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Parkinson Disease D010300 53 associated lipids
Psoriasis D011565 47 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Arthritis D001168 41 associated lipids
Lung Diseases D008171 37 associated lipids
Heart Failure D006333 36 associated lipids
Fever D005334 35 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Diarrhea D003967 32 associated lipids
Proteinuria D011507 30 associated lipids
Drug Eruptions D003875 30 associated lipids
Endometriosis D004715 29 associated lipids
Gastritis D005756 27 associated lipids
Gastrointestinal Hemorrhage D006471 27 associated lipids
Angina Pectoris D000787 27 associated lipids
Nasal Polyps D009298 26 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Stomach Neoplasms D013274 24 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Fibrosis D005355 23 associated lipids
Periodontitis D010518 22 associated lipids
Carcinoma, Lewis Lung D018827 22 associated lipids
Helicobacter Infections D016481 21 associated lipids
Bacterial Infections D001424 21 associated lipids
Myocardial Infarction D009203 21 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Tuberculosis D014376 20 associated lipids
Peptic Ulcer D010437 19 associated lipids
Ischemia D007511 18 associated lipids
Tuberculosis, Pulmonary D014397 18 associated lipids
Bronchial Spasm D001986 18 associated lipids
Dermatomycoses D003881 17 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
Synovitis D013585 15 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Encephalitis D004660 15 associated lipids
HIV Seropositivity D006679 15 associated lipids
Radiation Injuries D011832 14 associated lipids
Urticaria D014581 13 associated lipids
Rosacea D012393 13 associated lipids
Bradycardia D001919 13 associated lipids
Leishmaniasis, Visceral D007898 13 associated lipids
Abscess D000038 13 associated lipids
Endophthalmitis D009877 12 associated lipids
Wound Infection D014946 12 associated lipids
Otitis Media D010033 12 associated lipids
Skin Neoplasms D012878 12 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Liver Failure, Acute D017114 11 associated lipids
Shock, Septic D012772 11 associated lipids
Influenza, Human D007251 11 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Exanthema D005076 11 associated lipids
Lung Diseases, Obstructive D008173 10 associated lipids
Ureteral Obstruction D014517 10 associated lipids
Abnormalities, Drug-Induced D000014 10 associated lipids
Dermatitis, Exfoliative D003873 10 associated lipids
Hemophilia A D006467 10 associated lipids
Gastroesophageal Reflux D005764 10 associated lipids
Osteomyelitis D010019 10 associated lipids
Dyspnea D004417 10 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Hearing Disorders D006311 10 associated lipids
Pancreatitis D010195 10 associated lipids
Urethritis D014526 9 associated lipids
Urination Disorders D014555 9 associated lipids
Sinusitis D012852 9 associated lipids
Bacteremia D016470 9 associated lipids
AIDS-Related Opportunistic Infections D017088 9 associated lipids
Periodontal Pocket D010514 9 associated lipids
Obstetric Labor, Premature D007752 9 associated lipids
Otitis Media with Effusion D010034 9 associated lipids
Cross Infection D003428 9 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Leprosy D007918 8 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Zhang X and Hu C Selecting optimal columns for clarithromycin impurity analysis according to the quantitative relationship of hydrophobic subtraction model. 2017 J Pharm Biomed Anal pmid:28024686
Addo KK et al. Genotyping and drug susceptibility testing of mycobacterial isolates from population-based tuberculosis prevalence survey in Ghana. 2017 BMC Infect. Dis. pmid:29197331
Liu W et al. Rapid detection of mutations in erm(41) and rrl associated with clarithromycin resistance in Mycobacterium abscessus complex by denaturing gradient gel electrophoresis. 2017 J. Microbiol. Methods pmid:29079298
Koh WJ et al. Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease. 2017 Clin. Infect. Dis. pmid:28011608
Chang CH et al. Non-Tuberculous Mycobacteria Infection Following Autologous Fat Grafting on the Face. 2017 Aesthet Surg J pmid:29045552
Çekin AH et al. Use of probiotics as an adjuvant to sequential H. pylori eradication therapy: impact on eradication rates, treatment resistance, treatment-related side effects, and patient compliance. 2017 Turk J Gastroenterol pmid:28007678
Ikeue T et al. Pleuritis Caused by Mycobacterium kyorinense without Pulmonary Involvement. 2017 Intern. Med. pmid:28924121
Panozzo C et al. Chemicals or mutations that target mitochondrial translation can rescue the respiratory deficiency of yeast bcs1 mutants. 2017 Biochim. Biophys. Acta pmid:28888990
Emmanuel R et al. Antimicrobial efficacy of drug blended biosynthesized colloidal gold nanoparticles from Justicia glauca against oral pathogens: A nanoantibiotic approach. 2017 Microb. Pathog. pmid:29101061
Larsen EL et al. Clarithromycin, trimethoprim, and penicillin and oxidative nucleic acid modifications in humans: randomised, controlled trials. 2017 Br J Clin Pharmacol pmid:28185274
Ono S et al. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin. 2017 Helicobacter pmid:28098408
Gouin-Thibault I et al. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. 2017 J. Thromb. Haemost. pmid:27893182
Park J et al. Progression and Treatment Outcomes of Lung Disease Caused by Mycobacterium abscessus and Mycobacterium massiliense. 2017 Clin. Infect. Dis. pmid:28011609
Park SM et al. Randomized clinical trial comparing 10- or 14-day sequential therapy and 10- or 14-day concomitant therapy for the first line empirical treatment of Helicobacter pylori infection. 2017 J. Gastroenterol. Hepatol. pmid:27505301
Ishiguro N et al. Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients. 2017 PLoS ONE pmid:28288170
Attaran B et al. Effect of biofilm formation by clinical isolates of on the efflux-mediated resistance to commonly used antibiotics. 2017 World J. Gastroenterol. pmid:28275296
Chang CT et al. Antibiotic treatment of zebrafish mycobacteriosis: tolerance and efficacy of treatments with tigecycline and clarithromycin. 2017 J. Fish Dis. pmid:28422304
Furuya H et al. SAPHO syndrome-like presentation of disseminated nontuberculous mycobacterial infection in a case with neutralizing anti-IFNγ autoantibody. 2017 Rheumatology (Oxford) pmid:28371927
Ye JF et al. Evaluation of first-line bismuth-containing 7-day concomitant quintuple therapy for Helicobacter pylori eradication. 2017 J Dig Dis pmid:29119724
Chang KH et al. Comparison of antibiotic regimens in preterm premature rupture of membranes: neonatal morbidity and 2-year follow-up of neurologic outcome. 2017 J. Matern. Fetal. Neonatal. Med. pmid:27687157
Liatsos C and Leontiadis GII The "report card" to grade H. Pylori treatment regimens: is it achievable in real-world in areas with high clarithromycin resistance? 2017 J Gastrointestin Liver Dis pmid:28617893
Chew CA et al. The diagnosis and management of H. pylori infection in Singapore. 2017 Singapore Med J pmid:28536725
Gunnarsdottir AI et al. Antibiotic susceptibility of Helicobacter pylori in Iceland. 2017 Infect Dis (Lond) pmid:28440099
Oikawa R et al. Enrichment of Helicobacter pylori mutant strains after eradication therapy analyzed by gastric wash-based quantitative pyrosequencing. 2017 Tumour Biol. pmid:28990461
Radzikowska E et al. Cryptogenic organizing pneumonia-Results of treatment with clarithromycin versus corticosteroids-Observational study. 2017 PLoS ONE pmid:28945804
Chew KL et al. Predominance of clarithromycin-susceptible Mycobacterium massiliense subspecies: Characterization of the Mycobacterium abscessus complex at a tertiary acute care hospital. 2017 J. Med. Microbiol. pmid:28874233
Anwar HF et al. Synthesis of clarithromycin ketolides chemically modified at the unreactive C10-methyl group. 2017 Bioorg. Med. Chem. pmid:28302508
Turvey SL et al. Mycobacterium branderi infection: Case report and literature review of an unusual and difficult-to-treat non-tuberculous mycobacterium. 2017 Int. J. Infect. Dis. pmid:28268125
Kadota JI et al. The clinical efficacy of a clarithromycin-based regimen for Mycobacterium avium complex disease: A nationwide post-marketing study. 2017 J. Infect. Chemother. pmid:28254517
Quinn KL et al. Macrolides, Digoxin Toxicity and the Risk of Sudden Death: A Population-Based Study. 2017 Drug Saf pmid:28421551
Ramzy I et al. GENETIC MUTATIONS AFFECTING THE FIRST LINE ERADICATION THERAPY OF Helicobacter pylori-INFECTED EGYPTIAN PATIENTS. 2016 Rev. Inst. Med. Trop. Sao Paulo pmid:27982354
Kasai C et al. Changes in plasma ghrelin and leptin levels in patients with peptic ulcer and gastritis following eradication of Helicobacter pylori infection. 2016 BMC Gastroenterol pmid:27716077
Ferro BE et al. Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection. 2016 Antimicrob. Agents Chemother. pmid:27458221
Patton PH et al. Anti-tuberculous therapy for maintenance of remission in Crohn's disease. 2016 Cochrane Database Syst Rev pmid:27444319
Christl I et al. Clarithromycin and Tetracycline Binding to Soil Humic Acid in the Absence and Presence of Calcium. 2016 Environ. Sci. Technol. pmid:27438991
Laird-Fick HS et al. Gastric adenocarcinoma: the role of Helicobacter pylori in pathogenesis and prevention efforts. 2016 Postgrad Med J pmid:27222587
Xu J et al. Preparation, characterization and pharmacokinetics evaluation of clarithromycin-loaded Eudragit(®) L-100 microspheres. 2016 Eur J Drug Metab Pharmacokinet pmid:25652786
Berende A et al. Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease. 2016 N. Engl. J. Med. pmid:27028911
D'Erme AM et al. Successful treatment of rosacea fulminans in a 59-year-old woman with macrolide antibiotics and prednisone. 2016 Int. J. Dermatol. pmid:27028670
Belz D et al. Mycobacterium marinum infection initially diagnosed as metastatic Crohn's disease. 2016 J Eur Acad Dermatol Venereol pmid:25510444
Song Z et al. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy. 2016 Dig Liver Dis pmid:26847964
Vannarath S et al. Antibiotic Resistant Pattern of Helicobacter Pylori Infection Based on Molecular Tests in Laos. 2016 Asian Pac. J. Cancer Prev. pmid:26838225
Miyamoto S et al. Analysis of Helicobacter pylori genotypes in clinical gastric wash samples. 2016 Tumour Biol. pmid:26825980
Konstantinidis T et al. Immunomodulatory Role of Clarithromycin in Acinetobacter baumannii Infection via Formation of Neutrophil Extracellular Traps. 2016 Antimicrob. Agents Chemother. pmid:26643338
Ferro BE et al. Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin. 2016 Antimicrob. Agents Chemother. pmid:26643335
Wu TS et al. Postcesarean section wound infection caused by Mycobacterium massiliense. 2016 J Microbiol Immunol Infect pmid:26350122
Senatore FJ et al. Helicobacter pylori treatment: Still a work in progress. 2016 Postgrad Med pmid:26490697
Narita M et al. Antimicrobial Susceptibility of Microorganisms Isolated from Periapical Periodontitis Lesions. 2016 Bull. Tokyo Dent. Coll. pmid:27665691
Yoon H et al. Effects of N-acetylcysteine on First-Line Sequential Therapy for Helicobacter pylori Infection: A Randomized Controlled Pilot Trial. 2016 Gut Liver pmid:26347514
Liou JM et al. Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of in the community and hospital populations: a randomised trial. 2016 Gut pmid:26338825